Physician profile
Eric David Johnson
NPI 1649665399
$14,760.83
in general payments reported to CMS, 2019-2025
12 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.97 · 2021: $18.13 · 2023: $297 · 2024: $465 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,180 · Travel and Lodging: $6,281 · Food and Beverage: $1,026 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,180.00 |
| Travel and Lodging | $6,280.82 |
| Food and Beverage | $1,025.98 |
| Education | $195.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Btg International INC. | $13,854.05 | 2025 | Aurlumyn |
| Stryker Corporation | $305.37 | 2024 | Iconix |
| Astellas Pharma US INC | $169.98 | 2023 | |
| Viiv Healthcare Company | $132.32 | 2024-2025 | Apretude |
| Genzyme Corporation | $103.20 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $47.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $40.02 | 2024-2025 | Enhertu, Farxiga |
| Glaxosmithkline, LLC. | $31.42 | 2024-2025 | Arexvy, Shingrix |
| Amgen INC. | $23.58 | 2023 | Prolia, Evenity |
| Krystal Biotech INC | $22.79 | 2024 | Vyjuvek |
| Sobi, INC | $18.13 | 2021 | |
| Genentech USA, INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.